{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:15:26Z","timestamp":1783577726405,"version":"3.55.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Colorectal cancer liver metastases (CRLM) are a key driver of systemic immunosuppression and a determinant of poor prognosis. While surgical resection remains the mainstay of treatment, the dynamics of the immune landscape post-resection remain insufficiently characterized. This study aims to delineate immune reprogramming following liver resection in CRLM patients, offering insights into potential therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Peripheral blood samples were collected from CRLM patients before and after liver resection. Peripheral blood mononuclear cells were analyzed using multiparameter flow cytometry with adaptive and innate immunity panels, processed with FlowJo and FlowAI. Tumor immune microenvironment (TIME) was assessed by H&amp;amp;E, immunohistochemistry, and immunofluorescence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Postoperative analysis revealed remodeling of T cell composition, with a significant increased proportion of CD4+ T cells among circulating CD3+ T cells, including the CD28+ CD4+ subset, while regulatory T cells and T follicular helper cells remained unchanged. Overall proportion of CD8+ T cells among circulating CD3+ T cells was reduced. Among immune checkpoint-associated populations, the percentage of TIM3+ CD4+ T cells decreased significantly, whereas PD-1+ CD4+ T cells and exhausted PD-1+ TIM3+ double-positive T-cell subsets showed modest downward trends. Innate immune populations remained largely unchanged. Patients who experienced recurrence had higher postoperative proportion of S100A9+ monocytic myeloid-derived suppressor cells (M-MDSCs). Exploratory analyses further suggested that KRAS-mutated tumors may be associated with distinct postoperative immune profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Liver metastasis resection is associated with CD4+ T cell-dominant systemic immune remodeling and changes in exhaustion-associated markers, hypothetically suggesting a potential postoperative window for future immunotherapeutic interventions. Although highly speculative and requiring further functional validation, these findings suggest that the altered CD4+ T cell landscape warrants further investigation regarding its potential relevance to adoptive cellular therapies or immune checkpoint inhibition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1843400","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:34:17Z","timestamp":1783575257000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic immune remodeling following curative (R0) resection of colorectal liver metastases"],"prefix":"10.3389","volume":"17","author":[{"given":"Shuo","family":"Ren","sequence":"first","affiliation":[{"name":"Cancer Research Program, Research Institute of the McGill University Health Centre (RI-MUHC)","place":["Montreal, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Migmar","family":"Tsamchoe","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Cell Biology, McGill University","place":["Montreal, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie K.","family":"Petrillo","sequence":"additional","affiliation":[{"name":"Cancer Research Program, Research Institute of the McGill University Health Centre (RI-MUHC)","place":["Montreal, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oran","family":"Zlotnik","sequence":"additional","affiliation":[{"name":"Cancer Research Program, Research Institute of the McGill University Health Centre (RI-MUHC)","place":["Montreal, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Bloom","sequence":"additional","affiliation":[{"name":"Cancer Research Program, Research Institute of the McGill University Health Centre (RI-MUHC)","place":["Montreal, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Tsatoumas","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Cell Biology, McGill University","place":["Montreal, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vered","family":"Domankevich","sequence":"additional","affiliation":[{"name":"Alpha Tau Medical Ltd","place":["Jerusalem, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthoula","family":"Lazaris","sequence":"additional","affiliation":[{"name":"Cancer Research Program, Research Institute of the McGill University Health Centre (RI-MUHC)","place":["Montreal, QC, Canada"]},{"name":"Department of Surgery, McGill University","place":["Montreal, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Metrakos","sequence":"additional","affiliation":[{"name":"Cancer Research Program, Research Institute of the McGill University Health Centre (RI-MUHC)","place":["Montreal, QC, Canada"]},{"name":"Department of Anatomy and Cell Biology, McGill University","place":["Montreal, QC, Canada"]},{"name":"Department of Surgery, McGill University","place":["Montreal, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21772","article-title":"Colorectal cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4197","article-title":"Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases","volume":"22","author":"Frentzas","year":"2016","journal-title":"Nat Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30269-8","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial","volume":"17","author":"Stintzing","year":"2016","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s13046-023-02729-7","article-title":"Liver metastasis from colorectal cancer: pathogenetic development, immune landscape of the tumour microenvironment and therapeutic approaches","volume":"42","author":"Wang","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.01.030","article-title":"Liver transplantation immunology: Immunosuppression, rejection, and immunomodulation","volume":"78","author":"Montano-Loza","year":"2023","journal-title":"J Hepatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1152\/physrev.00004.2023","article-title":"The liver as a central \"hub\" of the immune system: pathophysiological implications","volume":"105","author":"Ronca","year":"2025","journal-title":"Physiol Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-022-00942-8","article-title":"Harnessing the liver to induce antigen-specific immune tolerance","volume":"44","author":"Gottwick","year":"2022","journal-title":"Semin Immunopathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0334-4","article-title":"Understanding, predicting and achieving liver transplant tolerance: from bench to bedside","volume":"17","author":"Thomson","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-16-0325","article-title":"Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-020-00486-7","article-title":"Bystander CD4(+) T cells: crossroads between innate and adaptive immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp Mol Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/31002","article-title":"T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions","volume":"393","author":"Schoenberger","year":"1998","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2611-3","article-title":"cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity","volume":"584","author":"Ferris","year":"2020","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02374-0","article-title":"CD4(+) T cells indirectly kill tumor cells via induction of cytotoxic macrophages in mouse models","volume":"68","author":"Bogen","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abe3348","article-title":"Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer","volume":"7","author":"Cachot","year":"2021","journal-title":"Sci Adv"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1287632","article-title":"Increased circulating regulatory T cells and decreased follicular T helper cells are associated with colorectal carcinogenesis","volume":"15","author":"Meng","year":"2024","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"101351","DOI":"10.1016\/j.jcmgh.2024.04.008","article-title":"Concomitant NAFLD facilitates liver metastases and PD-1-refractory by recruiting MDSCs via CXCL5\/CXCR2 in colorectal cancer","volume":"18","author":"Yang","year":"2024","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/s41419-021-03698-5","article-title":"Inhibition of CCL7 derived from Mo-MDSCs prevents metastatic progression from latency in colorectal cancer","volume":"12","author":"Ren","year":"2021","journal-title":"Cell Death Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1146\/annurev-med-051013-052304","article-title":"Regulation of tumor metastasis by myeloid-derived suppressor cells","volume":"66","author":"Condamine","year":"2015","journal-title":"Annu Rev Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01680","article-title":"The new era of cancer immunotherapy: targeting myeloid-derived suppressor cells to overcome immune evasion","volume":"11","author":"De Cicco","year":"2020","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00846-y","article-title":"Myeloid-derived suppressor cells in cancer and cancer therapy","volume":"21","author":"Lasser","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.21037\/atm-22-5270","article-title":"Single-cell transcriptome analysis of tumor immune microenvironment characteristics in colorectal cancer liver metastasis","volume":"10","author":"Geng","year":"2022","journal-title":"Ann Transl Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004688","article-title":"Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy","volume":"10","author":"Hwang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btw191","article-title":"flowAI: automatic and interactive anomaly discerning tools for flow cytometry data","volume":"32","author":"Monaco","year":"2016","journal-title":"Bioinformatics"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.100","article-title":"Vascularization of colorectal carcinoma liver metastasis: insight into stratification of patients for anti-angiogenic therapies","volume":"4","author":"Lazaris","year":"2018","journal-title":"J Pathol Clin Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/path.5449","article-title":"Neutrophils expressing lysyl oxidase-like 4 protein are present in colorectal cancer liver metastases resistant to anti-angiogenic therapy","volume":"251","author":"Palmieri","year":"2020","journal-title":"J Pathol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01061-1","article-title":"CD28 co-stimulation: novel insights and applications in cancer immunotherapy","volume":"24","author":"Lotze","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2174\/092986708784872384","article-title":"Storage, expression and function of Fas ligand, the key death factor of immune cells","volume":"15","author":"Lettau","year":"2008","journal-title":"Curr Med Chem"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-0206","article-title":"CD4 T-cell exhaustion: does it exist and what are its roles in cancer","volume":"27","author":"Miggelbrink","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217113","article-title":"Immunomodulatory molecules in colorectal cancer liver metastasis","volume":"598","author":"Kong","year":"2024","journal-title":"Cancer Lett"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00521-2","article-title":"CD4(+) T cells in cancer","volume":"4","author":"Speiser","year":"2023","journal-title":"Nat Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(02)00323-0","article-title":"The CD28 signaling pathway regulates glucose metabolism","volume":"16","author":"Frauwirth","year":"2002","journal-title":"Immunity"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8010071","article-title":"Transcriptomic profiling of tumor-infiltrating CD4(+)TIM-3(+) T cells reveals their suppressive, exhausted, and metastatic characteristics in colorectal cancer patients","volume":"8","author":"Sasidharan Nair","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.973418","article-title":"Neoadjuvant chemotherapy improves overall survival in resectable colorectal liver metastases patients with high clinical risk scores-- a retrospective, propensity score matching analysis","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"18738","DOI":"10.1038\/s41598-024-69546-6","article-title":"Impact of neoadjuvant chemotherapy on perioperative immune function in breast cancer patients: a propensity score-matched retrospective study","volume":"14","author":"Jiang","year":"2024","journal-title":"Sci Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101231","article-title":"Cancer-associated fibroblasts undergoing neoadjuvant chemotherapy suppress rectal cancer revealed by single-cell and spatial transcriptomics","volume":"4","author":"Qin","year":"2023","journal-title":"Cell Rep Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12943-021-01441-4","article-title":"Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer","volume":"20","author":"Zhu","year":"2021","journal-title":"Mol Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.02.008","article-title":"KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer","volume":"35","author":"Liao","year":"2019","journal-title":"Cancer Cell"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s44276-023-00007-9","article-title":"Circulating extracellular vesicles containing S100A9 reflect histopathology, immunophenotype and therapeutic responses of liver metastasis in colorectal cancer patients","volume":"1","author":"Tsamchoe","year":"2023","journal-title":"BJC Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1843400\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:34:19Z","timestamp":1783575259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1843400\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2026.1843400"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1843400","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"article-number":"1843400"}}